CHCWM – Cancer & Hematology Centers of West Michigan

RP-6306-02 (Repare Therapeutics)

Description:  Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors (MAGNETIC Study)

Mechanism of Action: PKMYT1 inhibitor (synthetically lethal with below genomic aberrations)  in combination with Gemcitabine

Target Patient Population:   Cancers with CCNE1 amplification, FBXW7 and or PPP2R1A deleterious mutations

Study Design:  Drug is given orally.  Gemcitabine is given IV Day 1, 8